Key Highlights

  • Total Revenue was USD 19.6 million, compared with USD 8.1 million.
  • Gross profit was USD 12.1 million, compared with USD 3.5 million.
  • Net loss was USD 32.7 million, compared with USD 19.5 million.
  • Unrestricted cash and marketable securities were USD 126.3 million.

Senseonics Holdings, Inc. (NASDAQ:SENS) reported third quarter 2026 total revenue of USD 19.6 million, compared with USD 8.1 million in the third quarter of 2025. Reported EPS was negative USD 0.50 and revenue was USD 19.56 million, compared with estimates of EPS of negative USD 0.52 and revenue of USD 16.20 million.

Revenue, net, was USD 19.3 million, compared with USD 4.2 million, and revenue from related parties was USD 0.2 million, compared with USD 3.9 million. Gross Profit was USD 12.1 million, compared with USD 3.5 million.

Losses and Operating Results

The company reports Eversense continuous glucose monitoring sales across its revenue lines. The operating loss was USD 31.9 million, compared with USD 19.6 million. The net loss was USD 32.7 million, compared with USD 19.5 million.

For the nine months ended September 30, 2026, total revenue was USD 45.8 million, compared with USD 21.0 million, and gross profit was USD 27.6 million, compared with USD 8.1 million. The operating loss was USD 99.7 million, compared with USD 47.4 million, and the net loss was USD 101.7 million, compared with USD 48.3 million. Nine month revenue, net, was USD 41.4 million, compared with USD 9.2 million, and revenue from related parties was USD 4.4 million, compared with USD 11.8 million.

As of September 30, 2026, the company had an accumulated Deficit of USD 1.1 billion and unrestricted cash, cash equivalents and marketable securities of USD 126.3 million. Management reported these balances in the Liquidity discussion of the filing. There were no unbilled amounts in Accounts Receivable from related parties, compared with USD 2.0 million at December 31, 2025.

Customer and Channel Mix

Sales to Ascensia accounted for 1.1% of total revenue in the third quarter, compared with 48.0% a year earlier, and 9.6% for the nine months, compared with 56.0%. No other individual customer, including any single distributor, accounted for 10% or more of total revenue in either period.

Sales under consignment arrangements accounted for 56.3% of total revenue in the quarter, compared with 46.5%, and 56.2% for the nine months, compared with 36.0%.

Following the amended and restated commercialization agreement, Ascensia has no further rights to revenues from sales of Eversense products in the United States. Effective January 1, 2026, the company is entitled to 100% of revenues from sales in the European territories, subject to transitional arrangements. In connection with the termination, the company accepted the return of certain unsold inventory previously held by Ascensia.

Corporate Background in the Filing

The filing notes a 1-for-20 Reverse Stock Split effective October 17, 2025 and a voluntary Withdrawal of the common stock from NYSE American to the Nasdaq Global Select Market, for which the company gave written notice on November 14, 2025. The cover page lists the common stock as registered on the Nasdaq stock market LLC.

Channel Mix and Balance Sheet

Senseonics's revenue of USD 19.6 million reflects a shift in mix away from Ascensia. The filing also reports the consignment share, USD 126.3 million in unrestricted cash and marketable securities and the accumulated deficit.